Clinical Remission with FF/UMEC/VI Versus ICS/LABA in Uncontrolled Asthma: The PERFORM Pragmatic Randomized Controlled Trial.
Stephen G Noorduyn, John J Oppenheimer, Alison C Moore et al.
✦ AI-curated · Sources linked
In 30 seconds
The PERFORM trial, a pragmatic randomized controlled trial, evaluated the effectiveness of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) in adults with uncontrolled asthma. At week 52, participants receiving FF/UMEC/VI had significantly greater odds of achieving clinical remission, with an adjusted odds ratio of 2.13 (95% CI 1.54, 2.94, P < 0.0001).
Key findings
- Participants on FF/UMEC/VI had an adjusted odds ratio of 2.13 for achieving clinical remission at week 52.
- The study included 1236 participants, with a mean age of 48.9 years and 68.6% female.
- Similar results were observed for alternative definitions of clinical remission.
- The safety profile at week 52 was consistent with previous studies.
Why it matters
This study provides evidence that single-inhaler triple therapy can significantly improve clinical remission rates in patients with uncontrolled asthma, which is crucial for optimizing asthma management and improving patient outcomes.